Abstracts tagged "interstitial lung disease"

Abstract Number: 2016 • ACR Convergence 2025
Effectiveness of Nintedanib combined with different DMARDs in joint and pulmonary domains of Rheumatoid Arthritis – Interstitial Lung Disease. National multicenter study of 74 patients
Ana Serrano-Combarro¹, Jesús Loarce², Belén Atienza-mateo³, Nuria Vegas Revenga⁴, Maria Martín López⁵, Santos Castañeda⁶, Rafael B. Melero-González⁷, Natalia Mena Vázquez⁸, Carmen Carrasco-Cubero⁹, Carolina Diez-Morrondo¹⁰, David Castro-Corredor¹¹, Tomas Ramon Vazquez Rodriguez¹², Andrea García-Valle¹³, Gema Bonilla¹⁴, Marina Rodríguez Lopez¹⁵, Ignacio Braña¹⁶, Pablo Andujar¹⁷, Sara Maria Rojas Herrera¹⁸, Juan Camilo Sarmiento-Monroy¹⁹, Diego Ferrer²⁰, Ivan Ferraz Amaro²¹ and Ricardo Blanco²², ¹Division of Rheumatology, Hospital Universitario Marques de Valdecilla, IDIVAL, Inmunopathology group, Santander, Santander, Spain, ²Ramón y Cajal University Hospital, Madrid, Spain, ³Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, PALMA DE MALLORCA/BALEARES, Spain, ⁴Galdakao- Usansolo University Hospital, Galdakao, Spain, ⁵Hospital ¹² de Octubre, Madrid, Spain, ⁶Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, ⁷COMPLEXO HOSPITALARIO UNIVERSITARIO DE OURENSE, O Carballino, Spain, ⁸Hospital Regional Universitario de Malaga, Malaga, Spain, Málaga, Spain, ⁹Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain, ¹⁰Complejo Asistencial Universitario de León, León, Spain, ¹¹Hospital General Universitario de Ciudad Real, Ciudad Real, Spain, ¹²Complejo Hospitalario Universitario de Ferrol, Ferrol, Spain, ¹³Rheumatology. Hospital General Río Carrión, Palencia, Castilla y Leon, Spain, ¹⁴Hospital Universitario La Paz, Rheumatology, Madrid, Madrid, Spain, ¹⁵Complejo Hospitalario Universitario de Santiago, Santiago, Spain, ¹⁶Hospital Universitario Central de Asturias, Oviedo, Spain, ¹⁷Hospital Universitario Doctor Peset, Valencia, Spain, ¹⁸Hospital de Mérida, Rheumatology, Badajoz, Badajoz, Spain, ¹⁹Hospital Clínic Barcelona, Barcelona, Spain, ²⁰Department of Pulmonology, Hospital Universitario Marques de Valdecilla, IDIVAL, Inmunopathology group, Santander, Santander, Spain, ²¹Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ²²Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain
Background/Purpose: Interstitial lung disease (ILD) is a severe complication of rheumatoid arthritis (RA) and its management remains a challenge. Approximately one third of the patients…
Abstract Number: 1749 • ACR Convergence 2025
External validation of a combined clinical and genetic risk score for the identification of interstitial lung disease in rheumatoid arthritis
Mikael Brink¹, Austin Wheeler², Bryant England² and Solbritt Rantapaa-Dahlqvist³, ¹Umeå Universitet, Umeå, Sweden, ²University of Nebraska Medical Center, Omaha, NE, ³Umeå University, Umea, Sweden
Background/Purpose: RA-associated interstitial lung disease (RA-ILD) causes substantial morbidity and mortality in RA. Despite this, a limited number of clinical and genetic risk factors have…
Abstract Number: 1561 • ACR Convergence 2025
Usefulness of HRCT in screening of interstitial lung disease in patients with systemic sclerosis without risk factors of clinical suspicion
Carlos de la Puente-Bujidos¹, Antia Garcia Fernandez², Verónica García García¹, Jesús Loarce³ and Sandra Garrote-Corral¹, ¹Ramón y Cajal University Hospital, Madrid, Spain, ²Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain, ³Ramón y Cajal University Hospital, Madrid, Spain
Background/Purpose: In 2019 a European expert consensus suggested that all patients with systemic sclerosis (SSc) should be screened with HRCT for interstitial lung disease (ILD)…
Abstract Number: 1201 • ACR Convergence 2025
Prognostic Significance of 1-Year Pulmonary Function Changes in Myositis-Associated Interstitial Lung Disease
Shiri Keret¹, Silvia Martinez Laverde², Irada Choudhuri², Raisa Lomanto Silva³, Eugenia Gkiaouraki², Tanya Chandra², Nantakarn Pongtarakulpanit⁴, Shreya Sriram², Niladri Bhowmick², Vaidehi Kothari², Kaushik Sreerama Reddy², Eaman Alhassan⁵, Anushka Aggarwal⁶, Maha Almackenzie⁷, Daniel Sullivan², Sara Faghihi-Kashani⁸, Koichi Yamaguchi², Daniel Kass², Kevin Gibson², Dana Ascherman⁹, Siamak Moghadam-Kia⁵, Chester V. Oddis⁹ and Rohit Aggarwal¹⁰, ¹Bnai Zion Medical Center, Atlit, Israel, ²University of Pittsburgh Medical Center, Pittsburgh, ³Massachusetts General Hospital, Boston, MA, ⁴Mahidol University, University of Pittsburgh, Bangkok, Thailand, ⁵University of Pittsburgh Medical Center, Pittsburgh, PA, ⁶Indraprastha Apollo Hospital, New Delhi, India, ⁷Medical Cities of the Ministry of the Interior, Riyadh, Saudi Arabia, ⁸UCSF, Mountain View, CA, ⁹University of Pittsburgh, Pittsburgh, PA, ¹⁰University of Pittsburgh, Rheumatology and Clinical Immunology, Pittsburgh, United States of America, Pittsburgh, PA
Background/Purpose: Lung involvement is the most frequent and severe extramuscular complication of Idiopathic Inflammatory Myopathy (IIM). The utility of pulmonary function test (PFT) monitoring for…
Abstract Number: 0689 • ACR Convergence 2025
Development of an Articular Activity Score in Systemic Sclerosis (ASSESS): Identifying Core Instruments for Disease Activity Assessment
Blaz Burja¹, Paco Welsing², Alain Lescoat³, Andreas Eisenring⁴, Anna-Maria Hoffmann-Vold⁵, Claire Leroy David⁶, Dinesh Khanna⁷, Francesco Del Galdo⁸, Michele Iudici⁹, Janet Pope¹⁰, julia Spierings¹¹, Madelon Vonk¹², Marie-Elise Truchetet¹³, Martine Clergeau¹⁴, Michael Hughes¹⁵, Susan Murphy¹⁶, Tracy Frech¹⁷, Oliver Distler¹⁸ and Muriel Elhai¹⁹, ¹Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Zurich, Switzerland, ²Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands, Utrecht, Netherlands, ³CHU Rennes - University Rennes, Rennes, France, ⁴Patient research partners, Zurich, Switzerland, ⁵Oslo University Hospital, Oslo, Norway, ⁶Patient research partners, Sos, France, ⁷University of Michigan, Ann Arbor, MI, ⁸University of Leeds, Leeds, United Kingdom, ⁹Division of Rheumatology, Department of Medicine, Faculty of Medicine, Geneva University Hospitals, Geneva, Switzerland, Geneva, ¹⁰University of Western Ontario, London, ON, Canada, ¹¹Department of Rheumatology & Clinical Immunology, University Medical Center, Ultrecht, The Netherlands, Utrecht, Netherlands, ¹²Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ¹³Bordeaux University Hospital, Bordeaux, France, ¹⁴Patient research partners, Paris, France, ¹⁵Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK, Manchester, England, United Kingdom, ¹⁶Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA, Michigan, ¹⁷Vanderbilt University Medical Center, Nashville, TN, ¹⁸Department of Rheumatology, University Hospital Zurich, University of Zurich, Switzerland, Zurich, Switzerland, ¹⁹Institute for Diagnostic and Interventional Radiology, University Hospital Zurich, University Zurich, Zurich, Switzerland, Schlieren, Switzerland
Background/Purpose: Inflammatory joint and/or tendon involvement affects up to 30% of patients with systemic sclerosis (SSc), resulting in pain, reduced joint function, and impaired patients'…
Abstract Number: 0247 • ACR Convergence 2025
Use of Nintedanib in Patients with Progressive Pulmonary Fibrosis
Elizabeth Volkmann¹, Steven Nathan², Karen Coeytaux³, Yanni Fan⁴, Jill Curran³, Haikun Bao³, Kamila Sroka-Saidi⁵, Ann Chauffe⁶ and Jeffrey J Swigris⁷, ¹Division of Rheumatology, Department of Medicine, University of California, David Geffen School of Medicine, Los Angeles, CA, USA, Los Angeles, CA, ²Inova Advanced Lung Disease and Transplant Program, Falls Church, VA, USA, Falls Church, ³Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA, Ridgefield, ⁴Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA, Ridgefield, CT, ⁵Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ⁶Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA, Newberry, FL, ⁷Center for Interstitial Lung Disease, Division of Pulmonary, Critical Care and Sleep Medicine, National Jewish Health, Denver, CO, USA, Denver
Background/Purpose: Nintedanib was approved in the US for the treatment of chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype (progressive pulmonary fibrosis [PPF])…
Abstract Number: 2662 • ACR Convergence 2025
Target trial emulation of biologic and targeted synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis-associated interstitial lung disease
Gregory McDermott¹, Daniel Solomon², Jeffrey Sparks³ and Rishi Desai³, ¹Brigham and Women's Hospital, Brookline, MA, ²Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA, ³Brigham and Women's Hospital, Boston, MA
Background/Purpose: RA-ILD is associated with high mortality, but the optimal treatment approach is unclear. While immunosuppressants may treat inflammatory components of ILD, there are concerns…
Abstract Number: 2249 • ACR Convergence 2025
Evaluation of a Screening Tool for Identifying Risk of Subclinical Interstitial Lung Disease in Rheumatoid Arthritis Patients Treated with Targeted Therapies
Marina Pavía-Pascual¹, Marina Sánchez-Lucas², Camille Bourgeois³, Maria Teresa Schiaffino Garcia-Villanova⁴, Julia Martínez Barrio⁵, Juan Molina-Collada⁶, Esther Chamorro De Vega⁷, José María álvaro-Gracia álvaro⁸ and Isabel Castrejón Fernández⁹, ¹Department of Rheumatology, Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain, Madrid, Madrid, Spain, ²Department of Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Madrid, Spain, ³Hospital general universitario Gregorio Marañon, Madrid, Madrid, Spain, ⁴Department of Immunology, Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain, Madrid, Madrid, Spain, ⁵Department of Rheumatology, Hospital Gregorio Marañón, Madrid, Spain, Madrid, Madrid, Spain, ⁶Department of Rheumatology, Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain, Madrid, Spain, ⁷Pharmacy department, Hospital General Universitario Gregorio Marañón.Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain, Madrid, Madrid, Spain, ⁸Department of Rheumatology, Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain. Department of Medicine, Complutense University, Madrid, Spain., Madrid, Madrid, Spain, ⁹MD, PhD, Madrid, Madrid, Spain
Background/Purpose: Interstitial lung disease (ILD) is the second leading cause of mortality in rheumatoid arthritis (RA) but often goes underdiagnosed due to its variable clinical…
Abstract Number: 1956 • ACR Convergence 2025
68Ga-FAPI-04 and 18F-FDG PET/ CT in MDA5 dermatomyositis-associated interstitial lung disease: a single-center, pilot study
Jia Li¹, Weijun Wei², Lianghua Li², Wenwen Xu³, Jianjun Liu² and Shuang Ye⁴, ¹Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (People's Republic), ²Department of Nuclear Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai ²⁰⁰²¹⁷, China., Shanghai, China (People's Republic), ³Department of Rheumatology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai ²⁰⁰²¹⁷, China., Shanghai, China (People's Republic), ⁴Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China, Shanghai, Shanghai, China (People's Republic)
Background/Purpose: Interstitial lung disease (ILD) is the leading cause of death in MDA5 dermatomyositis (MDA5-DM). Fibrosis and inflammation are pivotal drivers in the pathogenesis of…
Abstract Number: 1746 • ACR Convergence 2025
Inflammatory- and Fibrosis-Related Biomarkers and Rheumatoid Arthritis-Associated Interstitial Lung Disease Risk
Bryant England¹, Tate Johnson¹, Michael Duryee¹, Halie Frideres², Katherine Wysham³, Grant Cannon⁴, Gary Kunkel⁵, Dana Ascherman⁶, John Richards⁷, Paul Monach⁸, Gail Kerr⁹, Andreas Reimold¹⁰, Joshua Baker¹¹, Geoffrey Thiele¹ and Ted Mikuls¹, ¹University of Nebraska Medical Center, Omaha, NE, ²UNMC Department of Rheumatology, Omaha, NE, ³VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁴University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁵University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ⁶University of Pittsburgh, Pittsburgh, PA, ⁷Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, ⁸VA Boston Healthcare System, Boston, MA, ⁹Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ¹⁰Dallas VA Medical Center, Dallas, TX, ¹¹University of Pennsylvania, Philadelphia, PA
Background/Purpose: There exists a need to identify informative peripheral blood biomarkers for RA-interstitial lung disease (RA-ILD) and elucidate the pathophysiological processes driving RA-ILD onset. Several…
Abstract Number: 1556 • ACR Convergence 2025
Latent Profiles of Parenchymal Abnormalities and Vascular Features Measured by Quantitative CT Identifies a Subgroup of Systemic Sclerosis Patients With a Greater Lung Function Decline Over Time
Alicia Hinze¹, Nishanth Katurkuri², Robert Vassallo², Ami Shah³, Ryan Lennon², Brian Bartholmai² and Cynthia Crowson⁴, ¹Mayo Clinic - Rochester, MN, Rochester, MN, ²Mayo Clinic, Rochester, MN, ³Johns Hopkins Rheumatology, Baltimore, MD, ⁴Mayo Clinic, Stewartvillle, MN
Background/Purpose: The clinical course of interstitial lung disease (ILD) in systemic sclerosis (SSc) is highly variable--some patients experience progressive loss of lung function while others…
Abstract Number: 1199 • ACR Convergence 2025
Interstitial Lung Disease in Systemic Autoimmune Rheumatic Diseases (SARDs): Radiologic and Histologic Correlations
Darya S. Jalaledin¹, Aidan pye², Angela Chang², Navid Saleh², Saud AlHajeri³, Beatrice Daviault⁴, Arusa Shah⁵, Sabrina Hoa⁶, Océane Landon-Cardinal⁷, Alec Yu², Robert Levy⁸, Jennifer Wilson⁹, Charles Poirier⁴, James Choi², John Yee², Hyein Kim² and Kun Huang¹⁰, ¹Université de Montréal, Saint-Lambert, QC, Canada, ²University of British Columbia, VANCOUVER, BC, Canada, ³University of British Columbia, Vancouver, Canada, ⁴University of Montreal, Montreal, QC, Canada, ⁵University of Montreal, Montreal, BC, Canada, ⁶University of Montreal, Brossard, QC, Canada, ⁷Centre hospitalier de l'Université de Montréal, Montréal, QC, Canada, ⁸University of British Columbia, Deerfield, IL, ⁹UBC, Vancouver, BC, Canada, ¹⁰University of British Columbia, Vancouver, Surrey, BC, Canada
Background/Purpose: Systemic autoimmune rheumatic diseases (SARDs) are a major cause of interstitial lung disease (ILD), with high prevalence in inflammatory idiopathic myopathy (IIM), systemic sclerosis…
Abstract Number: 0688 • ACR Convergence 2025
Total lung capacity is predictive of disease severity and survival in systemic sclerosis: a longitudinal analysis in 2347 patients from the French National Cohort Study
Benjamin Chaigne¹, Alexandre bense², Frédérique Aubourg³, Christian AGARD⁴, Yannick Allanore⁵, Alice berezne¹, Gregory Pugnet⁶, Eric Hachulla⁷, Vincent Cottin⁸, Arnaud Hot⁸, bertrand Dunogue¹, Anuxcy Kanagaratnam², Sylvain Palat⁹, Alain Lescoat¹⁰, Sabine berthier¹¹, Emmanuel Chatelus¹², Sébastien Rivière¹³, David Launay¹⁴, Marie-Elise Truchetet¹⁵, Anh-Tuan Dinh-Xuan³ and Luc Mouthon¹, ¹Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Cochin University Hospital, Université Paris Cité, AP-HP, Paris, France, ²AP HP, Paris, France, ³Unité exploration fonctionnelle respiratoire, Pneumology department, Cochin Hospital, APHP, PARIS, France, ⁴Internal medicine, Nantes University Hospital, Nantes, France, ⁵Université Paris Cité, Paris, France, ⁶CHU, Montpelliers, France, ⁷CHU, Lilles, France, ⁸CHU, Lyon, France, ⁹Limoges, Limoges, France, ¹⁰CHU Rennes - University Rennes, Rennes, France, ¹¹CHU, Dijon, France, ¹²Department of Rheumatology, University Hospital Strasbourg, France, Strasbourg, France, ¹³AP HP, Parsi, France, ¹⁴Univ. Lille, Inserm, CHU Lille, Department of Internal Medicine and Clinical Immunology, Reference Center for Rare Autoimmune and Autoinflammatory diseases (CERAINOM), U¹²⁸⁶ - INFINITE - Institute for Translational Research in Inflammation, Lille, France. National Reference Center for Pulmonary Arterial Hypertension (Pulmotension), Lille, France, Lille Cedex, France, ¹⁵Bordeaux University Hospital, Bordeaux, France
Background/Purpose: Total lung capacity (TLC) is seldom assessed in the prediction of systemic sclerosis (SSc) disease severity.Herein, we utilized the French SSc national database to…
Abstract Number: 0169 • ACR Convergence 2025
The High Disease Burden of Connective Tissue Disorder-Interstitial Lung Disease in the USA Demonstrates an Unmet Need for Earlier Diagnosis and Treatment
Sally Wetten¹, George Mu², Keele E. Wurst³, Roger A. Levy⁴, Ben Newth⁵, Svetlana I. Nihtyanova⁶ and Elaine Irving⁷, ¹GSK, Epidemiology, Stevenage, United Kingdom, ²GSK, Statistics, Collegeville, PA, ³GSK, Immunology and Emerging Epidemiology, Durham, NC, ⁴GSK, Specialty Care, Global Medical Affairs, Collegeville, PA, ⁵GSK, Specialty Care, Global Medical Affairs, London, United Kingdom, ⁶GSK, Clinical Sciences, Research & Development, London, United Kingdom, ⁷GSK, Clinical, Stevenage, United Kingdom
Background/Purpose: Interstitial lung disease (ILD) is a serious pulmonary manifestation that can occur across all connective tissue disorders (CTD). Aberrant immune-mediated inflammation and fibrosis leads…
Abstract Number: 2661 • ACR Convergence 2025
Heterogeneity of RA-ILD by Longitudinal Forced Vital Capacity Measurements Is Associated with Survival and Respiratory Hospitalization
Bryant England¹, Yangyuna Yang¹, Punyasha Roul², Tate Johnson¹, Scott Matson³, Grant Cannon⁴, Brian Sauer⁵, Jeffrey Curtis⁶, Joshua Baker⁷ and Ted Mikuls¹, ¹University of Nebraska Medical Center, Omaha, NE, ²UNMC, Omaha, NE, ³University of Kansas, Kansas City, MO, ⁴University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁵Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁶Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL, ⁷University of Pennsylvania, Philadelphia, PA
Background/Purpose: Forced vital capacity (FVC) is one of the primary disease measures monitored in RA-associated interstitial lung disease (RA-ILD). While prior studies have suggested a…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].